Skip to search formSkip to main contentSkip to account menu

2'-cyano-2'-deoxyarabinofuranosylcytosine

Known as: 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine, 2'-cyano-2'deoxy-1-beta-D-arabinofuranosylcytosine, CNDAC 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Cytarabine

Narrower (1)

Nucleoside Analog DFP-10917
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations
PurposeThe mechanism of action of CNDAC (2′-C-cyano-2′-deoxy-1-β-d-arabino-pentofuranosyl-cytosine) is unique among deoxycytidine… 
2018
2018
Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofranocyl-cytosine (DFP-10917, CNDAC) is a 2'-deoxycytidine analog with antitumor activity… 
2017
2017
Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles
Background: Sapacitabine is a novel oral nucleoside analogue with a unique ability to induce single-strand DNA breaks after… 
2012
2012
Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine
Achieving improvements in survival and reducing relapse remains a challenge in acute myelogenous leukemia (AML) patients. This… 
2006
2006
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors
SummaryCS-682 (1-(2-C-cyano-2-deoxy-β-D-arabino-pentofuranosyl)-N4-palmitoylcytosine) is a novel orally administered 2… 
2005
2005
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) is a nucleoside analogue with a novel mechanism of action… 
Highly Cited
2004
Highly Cited
2004
Anti‐neovascular therapy by liposomal drug targeted to membrane type‐1 matrix metalloproteinase
Because membrane type‐1 matrix metalloproteinase (MT1‐MMP) is expressed specifically on the angiogenic endothelium as well as… 
2001
2001
Targeting and anti-tumor efficacy of liposomal 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in mice lung bearing B16BL6 melanoma.
1999
1999
Determinants in chemosensitivity of oncogene-transformed NIH3T3 cells to 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine.
2'-C-Cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC) is a novel 2'-deoxycytidine (dCyd) analogue with potent antitumor… 
1998
1998
Antitumor activity of 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine is enhanced by long-circulating liposomalization.
We previously synthesized the 5'-O-diacylphosphatidyl derivative of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)